Zobrazeno 1 - 10
of 224
pro vyhledávání: ''
Autor:
Zobair M. Younossi, Marc Bourliere, Linda Henry, Christophe Hézode, T. Asselah, Philippe Mathurin, Victor de Ledinghen, Maria Stepanova, Patrice Cacoub
Publikováno v:
Value in Health. 21:1218-1225
In addition to high efficacy, new anti-hepatitis C virus (HCV) regimens improve patient-reported outcomes (PROs), which must be considered by policymakers in different countries when deciding upon treatment coverage.To assess PROs of French patients
Publikováno v:
Value in Health. 24:S95-S96
Publikováno v:
Value in Health. 20:1110-1120
To evaluate the cost-utility of treatment with elbasvir/grazoprevir (EBR/GZR) regimens compared with ledipasvir/sofosbuvir (LDV/SOF), ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin (3D ± RBV), and sofosbuvir/velpatasvir (SOF/VEL) in pati
Publikováno v:
Value in Health. 24:S213
Publikováno v:
Value in Health. 24:S218
Publikováno v:
Value in Health. 23:S534
Publikováno v:
Value in Health. 23:S143
Autor:
J. Panic, L. Villa Zapata, Andrew Romero, Philip D. Hansten, Vignesh Subbian, John R. Horn, Daniel C. Malone, Richard D. Boyce, Sheila M. Gephart
Publikováno v:
Value in Health. 23:S147
Publikováno v:
Value in Health. 23:S149
Publikováno v:
Value in Health. 23:S97